Abstract
Tolerability of Human Immunoglobulin 10% Administered Subcutaneously Following Administration of Recombinant Human Hyaluronidase (rHuPH20) in Primary Immunodeficiency Disease (PIDD) Patients
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have